Peak Bio, Inc. (PKBO)

0.0086 0.0000 (0.00%) At close: 02:27PM EDT

Peak Bio, Inc.

4900 Hopyard Road
Suite 100
Pleasanton, CA 94588
United States
925-463-4800
https://peak-bio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 21

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Hoyoung Huh M.D., Ph.D.	Executive Chairman (Leave of Absence)	1.67M	N/A	1969
Dr. Stephen LaMond M.B.A., Pharm.D., PharmD MBA	Interim CEO, COO, Secretary & Director	499.17k	N/A	1962
Dr. Satyajit Mitra Ph.D.	Head of Oncology & Executive Director	317.22k	N/A	1974
Mr. Timothy M. Cunningham CPA, M.B.A.	Acting Chief Financial Officer	N/A	N/A	1963
Ms. Moddy Wong	Director of Human Resources	N/A	N/A	N/A
Ms. Divya Patel	Controller & Treasurer	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.

Corporate Governance

Peak Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.